Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed Not applicable Interventional

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NCT07043803
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
Interventions
Reduction of anticholinergic medication
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Altoona, Pennsylvania • Erie, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of Non-Invasive Positive Pressure Ventilation in Patients With Severe Obesity Undergoing Upper Endoscopy Procedures

NCT03529461
View directory record Official record
Conditions
Severe Obesity, Hypoxia
Interventions
Non-invasive positive pressure ventilation through nasal mask, Rescue non-invasive positive pressure ventilation through nasal mask, Secondary rescue maneuvers
Device · Other
Lead sponsor
Bristol Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

NCT00328783
View directory record Official record
Conditions
Breast Cancer
Interventions
Active Breathing Coordinator (ABC), Radiation Therapy
Device · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-438
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study

NCT04361240
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
Proton vs Photon Radiation
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional

Efficacy of Exercise for Sexual Side Effects of Antidepressants

NCT01189825
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 2 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
15
States / cities
La Jolla, California • Atlanta, Georgia • Des Moines, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Terminated Not applicable Interventional Results available

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

NCT00746252
View directory record Official record
Conditions
Bipolar Disorder
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
7 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

NCT01401985
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

NCT00345033
View directory record Official record
Conditions
Schizophrenia, Insulin Resistance
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Blood Vessels of the Heart

NCT00001638
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

Lifeflight: Fentanyl Versus Morphine

NCT00580489
View directory record Official record
Conditions
Pain Relief, Adverse Events
Interventions
either fentanyl or morphine
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

NCT07600762
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Nacresertib, Placebo for Nacresertib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
View directory record Official record
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 21, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Over-the-counter (OTC) Labels for Older Adults

NCT04345731
View directory record Official record
Conditions
Adverse Drug Event
Interventions
Over the counter drug labels
Other
Lead sponsor
Michigan State University
Other
Eligibility
65 Years to 110 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

NCT00360256
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

NCT03165409
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 21, 2026, 9:50 PM EDT